AXSM (Axsome Therapeutics) LT-Debt-to-Total-Asset: 0.21 (As of Mar. 2026)

What is Axsome Therapeutics LT-Debt-to-Total-Asset?

Axsome Therapeutics AXSM +1.83% 52 LT-Debt-to-Total-Asset is 0.21 as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Axsome Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.21.

Axsome Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.35) to Mar. 2026 (0.21). It may suggest that Axsome Therapeutics is progressively becoming less dependent on debt to grow their business.

Axsome Therapeutics (NAS:AXSM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Axsome Therapeutics LT-Debt-to-Total-Asset Related Terms

Axsome Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics LT-Debt-to-Total-Asset Chart

Axsome Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.56

0.28

0.32

0.33

0.21

Axsome Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.23	0.22	0.21	0.21

52GF Score

Axsome Therapeutics Inc AXSM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Axsome Therapeutics LT-Debt-to-Total-Asset Calculation

Axsome Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	145.134	/	689.805
	=	0.21

Axsome Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	146.079	/	713.607
	=	0.20

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.21 mean?

Axsome Therapeutics (AXSM) has a LT-Debt-to-Total-Asset of 0.21 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Axsome Therapeutics and its competitors.

Is Axsome Therapeutics' LT-Debt-to-Total-Asset too high?

Axsome Therapeutics' current LT-Debt-to-Total-Asset is 0.21. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Axsome Therapeutics' LT-Debt-to-Total-Asset compare to IONS and EXEL?

Axsome Therapeutics' LT-Debt-to-Total-Asset of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current LT-Debt-to-Total-Asset is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Axsome Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.21. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current LT-Debt-to-Total-Asset is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

LT-Debt-to-Total-Asset: 0.21
GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IONS EXEL MDGL BBIO BMRN ARWR SMMT CYTK ASND PRAX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 1AXSM:Italy 0HKF:UK 19X:Germany

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007

Website https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

52GF Score

Get the complete analysis for AXSM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$241.67

Price

$220.41

GF Value

View AXSM Analysis

See LT-Debt-to-Total-Asset data for all stocks →